- Home
- CHYM vs VTRS Comparison
CHYM vs VTRS Comparison
Compare CHYM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHYM
- VTRS
- Stock Information
- Founded
- CHYM 2012
- VTRS 1961
- Country
- CHYM United States
- VTRS United States
- Employees
- CHYM N/A
- VTRS N/A
- Industry
- CHYM Finance: Consumer Services
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- CHYM Finance
- VTRS Health Care
- Exchange
- CHYM Nasdaq
- VTRS Nasdaq
- Market Cap
- CHYM 10.8B
- VTRS 10.6B
- IPO Year
- CHYM 2025
- VTRS N/A
- Fundamental
- Price
- CHYM $30.09
- VTRS $9.15
- Analyst Decision
- CHYM Buy
- VTRS Hold
- Analyst Count
- CHYM 12
- VTRS 5
- Target Price
- CHYM $38.00
- VTRS $10.40
- AVG Volume (30 Days)
- CHYM 5.9M
- VTRS 10.6M
- Earning Date
- CHYM 08-07-2025
- VTRS 08-07-2025
- Dividend Yield
- CHYM N/A
- VTRS 5.26%
- EPS Growth
- CHYM N/A
- VTRS N/A
- EPS
- CHYM N/A
- VTRS N/A
- Revenue
- CHYM $1,800,041,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- CHYM N/A
- VTRS N/A
- Revenue Next Year
- CHYM N/A
- VTRS $1.85
- P/E Ratio
- CHYM N/A
- VTRS N/A
- Revenue Growth
- CHYM 30.88
- VTRS N/A
- 52 Week Low
- CHYM $28.21
- VTRS $6.85
- 52 Week High
- CHYM $44.94
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- CHYM N/A
- VTRS 54.81
- Support Level
- CHYM N/A
- VTRS $9.17
- Resistance Level
- CHYM N/A
- VTRS $9.39
- Average True Range (ATR)
- CHYM 0.00
- VTRS 0.21
- MACD
- CHYM 0.00
- VTRS 0.00
- Stochastic Oscillator
- CHYM 0.00
- VTRS 63.82
About CHYM Chime Financial Inc. Class A Common Stock
Chime Financial Inc is a financial technology company that believes in core banking services.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.